We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

New Mechanism Causes Both Inflammation and Immunosuppression in Tumors

Before introducing EP2/4 inhibitor drug. Credit: Kyoto University/ Global Comms

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "New Mechanism Causes Both Inflammation and Immunosuppression in Tumors"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 

If cancerous cells started wreaking havoc in your body, like terrorists in a building, your immune system would act like a SWAT team to combat the enemy.


But what if the building entrance were blocked by a mysterious conspirator? The terrorists would surely be able to continue their evil deeds inside the building.


Now, researchers at Kyoto University have identified the mechanism by which active inflammation occurs in parallel with immunosuppression -- the conspirator that blocks the entrance-- in the tumor microenvironment or TME.


Single-cell RNA sequencing was used to analyze the action mechanism of the inhibitors of prostaglandin E2 receptor in mouse models. Results showed reduced gene expression of regulatory T cell or Treg, a strong immunosuppressive cell, involved in immunosuppression.


"We discovered that EP2/EP4 inhibitors suppressed tumor growth in mouse models by allowing Treg to infiltrate the tumor and activate there," explains lead author Dean Thumkeo of the Department of Drug Discovery Medicine.


To put the results into human perspective, publicly accessible data indicate that some patients with either lung, ovarian, breast, or liver cancers have high EP2/EP4 expression levels.


"What is important is that EP2/EP4 expression was positively correlated with the expression of genes related to Treg recruitment and activation in these cancer patients," adds Thumkeo.


This correlation suggests to the researchers that patients with high EP2/EP4 expression suffer from a TME that highly suppresses the immune system, suggesting that cancer treatment employing EP2/EP4 inhibitors might benefit some patients with these cancers.


Currently, immune checkpoint inhibitors, or ICIs, which target the immune system rather than the cancer cells, appear to be the new go-to cancer treatment. Typically, about a quarter of cancer patients show a significant response to ICIs. For the remaining portion of patients, EP2/EP4 inhibitors may be a potential alternative.


"For now, the discovery of the anti-immunosuppressants gives us a new way forward in exploring cancer therapeutics beyond ICIs," concludes Thumkeo.


Reference: Thumkeo D, Punyawatthananukool S, Prasongtanakij S, et al. PGE2-EP2/EP4 signaling elicits immunosuppression by driving the mregDC-Treg axis in inflammatory tumor microenvironment. Cell Rep. 2022;39(10). doi: 10.1016/j.celrep.2022.110914


This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

 
Advertisement